Trial reportAnnals of surgery2014
Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success.
Trial report in Annals of surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01423877 (Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35), which is not on this map. Cited by 53 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35
Who cites it
53 citing papers in PubMed, 5 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- SICOB Italian clinical practice guidelines for the surgical treatment of obesity and associated diseases using GRADE methodology on bariatric and metabolic surgery.Updates in surgery · 2025Guideline
- Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- The Impact of Bariatric Surgery Versus Non-Surgical Treatment on Blood Pressure: Systematic Review and Meta-Analysis.Obesity surgery · 2021Pooled it
- A Systematic Review of One Anastomosis/Mini Gastric Bypass as a Metabolic Operation for Patients with Body Mass Index ≤ 35 kg/mObesity surgery · 2020Pooled it
- The comprehensive summary of surgical versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomized controlled trials.Oncotarget · 2016Pooled it
- Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial.Reproductive sciences (Thousand Oaks, Calif.) · 2025Trial
- Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study.Frontiers in endocrinology · 2023Trial
- Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2018Trial
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.The New England journal of medicine · 2017Trial
- Metabolic bariatric surgery pays off: a longitudinal analysis of weight loss and HbA1c changes in real-world patients data in the West of Scotland.International journal of obesity (2005) · 2026Article
- Metabolic and Bariatric Surgery for Class I Obesity (Body Mass Index 30-34.9 kg/mJournal of metabolic and bariatric surgery · 2025Review
- How Do Trauma- and Violence-Informed Care Approaches Underpin Bariatric Surgery Interventions for Type 2 Diabetes Mellitus Remission? A Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Article
- Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- The Advanced Glycation End-Products (AGE)-Receptor for AGE System (RAGE): An Inflammatory Pathway Linking Obesity and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Recent progress of remission in type 2 diabetes.Therapeutic advances in endocrinology and metabolism · 2025Review
- Metabolic and bariatric surgeries in individuals with obesity and BMI of 30-35 kg/m2: systematic review.Revista da Associacao Medica Brasileira (1992) · 2025Article
- The RAGE/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease.Cardiovascular research · 2024Review
- Bariatric Surgery for Patients with Overweight/Obesity. A Comprehensive Grading Methodology and Network Metanalysis of Randomized Controlled Trials on Weight Loss Outcomes and Adverse Events.Obesity surgery · 2023Review
- Metabolic Surgery in Korea.Journal of metabolic and bariatric surgery · 2023Review
- Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities.Journal of applied physiology (Bethesda, Md. : 1985) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveTo compare bariatric surgery versus intensive medical weight management (MWM) in patients with type 2 diabetes mellitus (T2DM) who do not meet current National Institutes of Health criteria for bariatric surgery and to assess whether the soluble form of receptor for advanced glycation end products (sRAGE) is a biomarker to identify patients most likely to benefit from surgery.
backgroundThere are few studies comparing surgery to MWM for patients with T2DM and BMI less than 35.
methodsFifty-seven patients with T2DM and BMI 30 to 35, who otherwise met the criteria for bariatric surgery were randomized to MWM versus surgery (bypass, sleeve or band, based on patient preference). The primary outcomes assessed at 6 months were change in homeostatic model of insulin resistance (HOMA-IR) and diabetes remission. Secondary outcomes included changes in HbA1c, weight, and sRAGE.
resultsThe surgery group had improved HOMA-IR (-4.6 vs +1.6; P = 0.0004) and higher diabetes remission (65% vs 0%, P < 0.0001) than the MWM group at 6 months. Compared to MWM, the surgery group had lower HbA1c (6.2 vs 7.8, P = 0.002), lower fasting glucose (99.5 vs 157; P = 0.0068), and fewer T2DM medication requirements (20% vs 88%; P < 0.0001) at 6 months. The surgery group lost more weight (7. vs 1.0 BMI decrease, P < 0.0001). Higher baseline sRAGE was associated with better weight loss outcomes (r = -0.641; P = 0.046). There were no mortalities.
conclusionsSurgery was very effective short-term in patients with T2DM and BMI 30 to 35. Baseline sRAGE may predict patients most likely to benefit from surgery. These findings need to be confirmed with larger studies.ClinicalTrials.gov ID: NCT01423877.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.